首页|期刊导航|中国合理用药探索|芪苈强心胶囊联合替格瑞洛片对2型糖尿病合并冠心病患者血小板活化因子及心外膜脂肪衰减值的影响

芪苈强心胶囊联合替格瑞洛片对2型糖尿病合并冠心病患者血小板活化因子及心外膜脂肪衰减值的影响OA

Effects of Qiliqiangxin Capsules Combined with Ticagrelor Tablets on Platelet Activation Markers and Epicardial Fat Attenuation in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease

中文摘要英文摘要

目的:探究芪苈强心胶囊联合替格瑞洛片对2型糖尿病合并冠心病患者血小板活化因子及心外膜脂肪衰减值(EFat)的影响.方法:选取 2023年1月~2025年1月本院收治的86例2型糖尿病合并冠心病患者作为研究对象,采用随机数字表法分为对照组(n=43,给予常规治疗+替格瑞洛片治疗)和联合组(n=43,给予常规治疗+替格瑞洛片+芪苈强心胶囊治疗),两组均治疗4周.对比分析两组中医证候评分、血小板活化因子[溶酶体相关膜蛋白3(CD63)、P选择素(CD62P)]、EFat、皮下脂肪平均计算机断层扫描(CT)衰减值、心肌功能[左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)、左心室射血分数(LVEF)]、炎症因子[Toll样受体3(TLR3)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)]及不良反应发生情况.结果:治疗4周后,两组各项中医证候评分、CD63、CD62P、EFat、皮下脂肪平均CT衰减值、LVESV、LVEDV、TLR3、hs-CRP和TNF-α均降低,且联合组低于对照组(P<0.05);LVEF均升高,且联合组高于对照组(P<0.05).两组不良反应总发生率比较无统计学差异(P>0.05).结论:芪苈强心胶囊联合替格瑞洛片可有效降低2型糖尿病合并冠心病患者血小板活化因子及EFat,改善心肌功能,减轻炎症反应,且未增加不良反应发生风险.

Objective:To investigate the effects of Qiliqiangxin capsules combined with ticagrelor tablets on platelet activation markers and epicardial fat attenuation(EFat)in patients with type 2 diabetes mellitus and coronary heart disease.Methods:A total of 86 patients with type 2 diabetes mellitus and coronary heart disease who were admitted to our hospital between January 2023 and January 2025 were enrolled.Using a random number table,the patients were assigned to a control group(n=43,conventional therapy plus ticagrelor tablets)or a combination group(n=43,conventional therapy plus ticagrelor tablets and Qiliqiangxin capsules).Both groups were treated for 4 weeks.Traditional Chinese medicine(TCM)syndrome scores;platelet activation markers[lysosome-associated membrane protein 3(CD63)and P-selectin(CD62P)];EFat;mean computed tomography(CT)attenuation of subcutaneous fat;cardiac function parameters[left ventricular end-systolic volume(LVESV),left ventricular end-diastolic volume(LVEDV),and left ventricular ejection fraction(LVEF)];inflammatory markers[Toll-like receptor 3(TLR3),high-sensitivity C reactive protein(hs-CRP),and tumor necrosis factor-α(TNF-α)];and the incidence of adverse reactions were compared between the groups.Results:After 4 weeks of treatment,all TCM syndrome scores and the levels or values of CD63,CD62P,EFat,mean CT attenuation of subcutaneous fat,LVESV,LVEDV,TLR3,hs-CRP,and TNF-α decreased in both groups and were lower in the combination group than in the control group(P<0.05).LVEF increased in both groups and was higher in the combination group than in the control group(P<0.05).The overall incidence of adverse reactions did not differ significantly between the groups(P>0.05).Conclusion:Qiliqiangxin capsules combined with ticagrelor tablets effectively reduced platelet activation markers and EFat,improved cardiac function,and attenuated inflammatory responses in patients with type 2 diabetes mellitus and coronary heart disease without increasing the risk of adverse reactions.

尹云平;聂晓东;王珊珊;黄浩;任培

河南省第二人民医院,郑州 451191河南省第二人民医院,郑州 451191河南省第二人民医院,郑州 451191河南省第二人民医院,郑州 451191河南省第二人民医院,郑州 451191

医药卫生

芪苈强心胶囊替格瑞洛片2型糖尿病冠心病血小板活化因子心外膜脂肪衰减值

Qiliqiangxin capsulesticagrelor tabletstype 2 diabetes mellituscoronary heart diseaseplatelet activation markersepicardial fat attenuation

《中国合理用药探索》 2026 (8)

43-49,7

河南省医学科技攻关计划项目(LHGJ20201128)

10.3969/j.issn.2096-3327.2026.08.007

评论